Stage IIIA Skin Melanoma Recruiting Phase 1 / 2 Trials for DB08911 (Trametinib)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01989585Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment